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Abstract The design of smaller functional mimics of large 
proteins has long been an important challenge. In this study we 
use the natural leucine zipper as a structural template to design a 
31-residue peptide analog that mimics the function of the larger 
platelet factor 4 (PF4) protein. The heparin binding activity of 
PF4 has been introduced into an unrelated leucine zipper 
sequence only by virtue of incorporating four lysines of PF4. 
Circular dichroism and binding experiments have shown that the 
designed leucine zipper peptide adopts a stable helical conforma-
tion and shows significant PF4-like heparin binding activity. 
These results strongly suggest that the lysine residues play an 
important role in the binding of PF4 to heparin. The de novo 
generation of the PF4 function in a designed leucine zipper 
peptide demonstrates that the leucine zipper motif is a useful 
scaffold for the design of functional peptides and proteins. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The de novo design of peptides and proteins with desired 
structure and biological function has been an elusive goal. 
Following the general concept that the amino acid sequence 
of a protein determines the protein's three-dimensional struc-
ture, and that the structure confers the biological function [1], 
many studies have attempted to understand the path from 
sequence to structure and function. Extensive progress has 
been made in elucidating the path from sequence to structure 
with the studies of de novo designed peptides and proteins [2-
5]. With the advent of these designed structural proteins, at-
tempts have also been made to introduce biological functions 
into these de novo sequences [6-8]. However, since the de 
novo proteins designed from scratch often fold into the stage 
of the 'molten globule' which lacks a unique tertiary structure, 
the functional proteins designed based on the 'molten globule' 
stage of the de novo sequences are generally much less active 
than their native counterparts. 
In view of the current limitation in the ability to design 
native-like structures from first principles, an alternative strat-
egy is the natural motif approach in which active or binding 
sites of a target protein are grafted onto unrelated, pre-exist-
ing sequence templates to generate novel biological functions. 
By exploiting the structural motifs already designed by nature, 
one skips the uncertain step of going from sequence to struc-
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ture and thus avoids the problem of the 'molten globule' 
common to the structures designed from scratch. The use of 
stable natural motifs with well-defined tertiary structures may 
offer similar or enhanced biological activity and stability rel-
ative to native proteins. One potential application of this nat-
ural motif approach is in the design of a smaller peptide that 
could mimic and dissert the function of a larger protein, an 
emerging field that has recently attracted extensive attention 
[9-11]. The use of an unrelated motif, which has little se-
quence homology to the target protein that it is designed to 
mimic, provides a simplified system to dissert complex bio-
logical functions and test hypothetical models of a particular 
structure-function relationship. In addition, the natural mo-
tifs used in our study are generally small in size (20-60 amino 
acids) and are amenable to synthetic chemistry. Therefore, 
they may be valuable intermediate targets for the subsequent 
development of small nonpeptide mimics. 
As a test of the small natural motif approach to functional 
protein design, we have chosen the heparin binding activity of 
platelet factor 4 (PF4) as a target function. PF4 is a 70-amino-
acid protein that belongs to the family of chemokines [12,13]. 
In addition to the specific binding to heparin, PF4 has been 
implicated in a number of biological activities including rever-
sal of heparin anticoagulation [14], reversal of immunosup-
pression [15], inhibition of angiogenesis [16] and suppression 
of myeloid progenitor cell proliferation [17]. The structure of 
PF4 is known and many studies have been carried out to 
elucidate the residues important for heparin binding. It has 
been suggested that two pairs of lysine residues in the C-ter-
minal helix of PF4 are important for binding heparin [12]. 
The natural structural motif we have chosen to design the 
heparin binding activity of PF4 is the GCN4 leucine zipper. 
The leucine zipper motif, first described by Landschulz et al. 
[18], has been shown to consist of a stable dimer of amphi-
philic helices that form a coiled-coil [19,20]. Peptide fragments 
from the GCN4 leucine zipper form a remarkably stable and 
precise conformation in aqueous solution that has been deter-
mined by NMR and crystallography [21,22]. Comparison of 
the crystal structures for PF4 [23] and GCN4 leucine zipper 
peptide showed a close similarity in the orientations of the 
helices (Fig. 1A). This prompted us to hypothesize that the 
incorporation of the proposed required lysines of PF4 into the 
leucine zipper motif (which has unrelated function and se-
quence) may generate a new surface for heparin binding. To 
test this, a peptide was designed (PF4zip) consisting of the 
sequence for the GCN4 leucine zipper with four lysine resi-
dues substituted in positions that mimic the positions of the 
four required lysines in human PF4 without disrupting the 
residues involved in forming the leucine zipper (Fig. IB). In 
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addition, a peptide with the native sequence for the GCN4 
leucine zipper (GCN4zip) was also synthesized as a control. 
2. Materials and methods 
2.1. Peptide synthesis 
Both GCN4zip and PF4zip were prepared by solid phase peptide 
synthesis with Fmoc-strategy using a PerSeptive Biosystems 9050 pep-
tide synthesizer (PerSeptive Biosystems, Milford, MA) and Fmoc-Gly-
PEG-PS resin (PerSeptive Biosystems, loading = 0.16 mEq/g). The 
side-chain-protecting groups of Να-Fmoc amino acids were: Arg, 
Pmc; Asn, Trt; Asp, OtBu; Cys, Trt; Gin, Trt; Glu, OtBu; His, 
Trt; Lys, Boc; Ser, tBu and Tyr, tBu (Pmc = 2,2,5,7,8-pentamethyl-
chroman-6-sulfonyl, Trt = trityl, OtBu = tert-b\xty\ ester, Boc = tert-bu-
tyloxycarbonyl and tBu = tert-butyl ether). The Να-Fmoc amino acids 
(4 equiv.) were sequentially added as a preactivated solution of O-
(7-azabenzotriazol-1 -yl)-1,1,3,3-tetramethyluronium hexafluorophos-
phate (HATU) and diisopropylethylamine (DIPEA) to the resin 
(660 mg, 0.25 mmol). JV-Methyl-2-pyrrolidinone (NMP) was used as 
solvent and 20-50% piperidine in NMP was used to remove the pro-
tected Fmoc groups. Upon completion of all synthetic cycles, resin 
Fig. 1. A: Comparison of the crystal structure of PF4 dimer with the crystal structure of the GCN4 leucine zipper dimer modified to include 
the lysines proposed to be essential for heparin binding. For clarity, a dimer instead of the actual tetramer of PF4 seen in the crystal structure 
is shown. The lysine side chains important for heparin binding are highlighted in a ball and stick model. Structures were displayed using the 
Insight II software package (Biosym, Inc. San Diego, CA). B: Sequences of the designed leucine zipper peptide (PF4zip) as compared to the na-
tive PF4 protein and the control leucine zipper peptide (GCN4Z¡P). Residues altered in PF4Z¡P are shown in red. 
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was removed from the reaction vessel and treated with reagent K 
(trifluoroacetic acid (TFA): phenol: thioanisole: ethandithiol: H 2 0 / 
10: 0.75: 0.5: 0.25: 0.5) for 2 h at room temperature with gentle 
stirring. The mixture was then filtered directly into ice-cold ethyl 
ether. The resulting suspension was transferred into a centrifuge 
tube and centrifuged for 10 min. at 2000 Xg at room temperature. 
The supernatant was discarded and the precipitate was resuspended 
in ethyl ether, and again centrifuged for 5 min. The procedure was 
repeated twice before the precipitate was dissolved in 5% acetic acid/ 
water and lyophilized. The crude peptide was purified by preparative 
HPLC using a Dynamax-300Ä C18 column (241 X 22 mm ID, 15 μpiι 
spherical packing at a flow rate of 9 ml/min), with UV detection 
(220 nm). Two HPLC solvents—solvent A (d.i. H2O/0.1% TFA) and 
B (acetonitrile/0.1% TFA)—were used in a programmed gradient of 
5-25% B over 40 min. (0.5%/min.). The fractions containing the pep-
tide were pooled together and lyophilized. 
2.2. Heparin binding assays 
Following the procedure of Rucinski et al. [24] 125I-labeled peptides 
were bound to a heparin-sepharose column in 0.02 M Tris-HCl buffer 
pH 7.0 containing 0.05 M NaCl. The column was extensively washed 
with the binding buffer and bound peptide was eluted with a 0.1-2 M 
NaCl gradient. 
2.3. CD spectroscopy 
All spectra were recorded using a Jasco J710 circular dichroism 
spectrometer with a 0.01 cm pathlength quartz cuvette. 40-60 μΜ 
peptide solutions were prepared in 3 mM sodium citrate, 3 mM so-
dium phosphate, and 3 mM sodium borate buffer at pH 6.11. Peptide 
concentrations were determined by tyrosine absorbance in 6 M gua-
nidine hydrochloride assuming an extinction coefficient at 276 nm of 
1500 M _ 1 cm - 1 [25]. Three scans were acquired and accumulated 
from 189 to 250 nm, at 0.1 nm resolution. Thermal stability of the 
peptides were determined by monitoring the change in [Θ]222 as a 
function of temperature. The temperature was increased at an interval 
of 2°C with an equilibration time of 2 min. The temperature depend-
ence (Tm) was determined from the minima of the first derivative of 
[Θ]222 with T _ 1 , where T is in K [26]. 
3. Results 
The heparin binding activity of the designed leucine zipper 
peptide PF4 z i p was measured by retention on a heparin-agar-
ose column in the presence of increasing NaCl concentrations. 
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Fig. 2. Heparin binding of the designed leucine zipper peptide 
(PF4zip) ( · ) as compared to the control leucine zipper peptide 
(GCN4zip) (■) as well as native PF4 ( A ) . For the assay,
 125I-labeled 
peptides were bound to a heparin-sepharose column in 0.02 M 
Tris-HCl buffer pH 7.0 containing 0.05 M NaCl. The column was 
extensively washed with the binding buffer and bound peptide was 
eluted with a 0.1-2 M NaCl gradient. 
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Fig. 3. CD Spectra of PF4zip ( · ) as compared to GCN4zip (■) and 
PF458_7o ( ♦ ) . These spectra were recorded using a Jasco J710 circu-
lar dichroism spectrometer with a 0.01 cm pathlength quartz cu-
vette. 40-60 μΜ peptide solutions were prepared in 3 mM sodium 
citrate, 3 mM sodium phosphate, and 3 mM sodium borate buffer 
at pH 6.11. Peptide concentrations were determined by tyrosine ab-
sorbance in 6 M guanidine hydrochloride assuming an extinction 
coefficient at 276 nm of 1500 M _ 1 cm - 1 . Three scans were acquired 
and accumulated from 189-250 nm, at 0.1 nm resolution. As shown, 
the CD intensity of —33000 deg cm2 dmol - 1 at 222 nm for 
GCN4zip suggests that the peptide is essentially 100% a-helical 
[34,35], which is identical to the leucine zipper studied by O'Shea et 
al. [19]. The CD intensity of -27000 deg cm2 dmol - 1 at 222 nm 
for PF4zip, suggests that the peptide is 80% a-helical. The CD spec-
trum of the peptide containing the C-terminal helix of PF4 
(PF458_7o) suggests that the peptide is random coil. 
Fig. 2 shows that radiolabeled PF4 z i p binds with high affinity 
to heparin-sepharose since it is eluted at about 1.4 M NaCl . 
Native PF4 also elutes at about 1.4 M NaCl . These data 
suggest that the designed leucine zipper peptide strongly binds 
heparin like the native PF4 protein. In contrast, no heparin 
binding activity is observed in the control native leucine zip-
per peptide GCN4 z i p which contains an identical amino acid 
sequence except for the three modified lysine residues (Fig. 2). 
These results demonstrate that the remarkable heparin bind-
ing activity of the designed leucine zipper peptide is specifi-
cally due to the introduction of the lysine residues. Fur ther in 
vitro functional assay studies have shown that the designed 
leucine zipper peptide also reverses heparin anticoagulation, 
as determined by the activated partial thromboplast in time 
(APTT), while the control leucine zipper peptide does not 
have such activity (unpublished results). 
In order to determine the structural basis for the observed 
heparin binding activity of the designed leucine zipper pep-
tide, we have carried out circular dichroism (CD) experiments 
to investigate the solution conformation of this peptide. The 
C D spectrum of this peptide is shown in Fig. 3. The double 
minima at 208 and 222 n m and the maximum at 195 n m 
indicate that the peptide adopts a highly helical conformation 
in aqueous solution. In addition, the peptide displays a two-
state melting profile which is typical for a fully folded native 
protein (unpublished results). The T m for GCN4 z i p is 55°C 
and 42°C for PF4 z i p . The result for GCN4 z i p correlates with 
the observations of O'Shea et al. [19]. These results demon-
strate that the designed leucine zipper peptide maintains a 
native-like helical conformation of the leucine zipper template. 
To further investigate the importance of this helical confor-
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mation for heparin binding activity, we studied the solution 
conformation of a peptide comprising the C-terminal helix of 
PF4 (PF45g_7o). Although this peptide contains the binding 
domain of PF4 with the four lysines proposed as heparin 
binding sites, the peptide has very low binding affinity for 
heparin, eluting at 0.2 M NaCl and is able to reverse heparin 
anticoagulation only about 20% at relatively higher concen-
trations. CD spectrum of the peptide shows that it displays a 
random coil conformation. This explains the loss of binding 
activity of the peptide and confirms the importance of the 
helical conformation as a framework for presenting the hep-
arin binding lysine side chains. 
In addition to the heparin binding activity, we tested the 
designed leucine zipper peptide for other PF4-related biolog-
ical functions in vitro. The designed leucine zipper peptide 
was shown to have no effect on neutrophil activation (unpub-
lished results). It is known that, while native PF4 does not 
activate neutrophils, N-terminally modified PF4 containing 
ELR sequence [27,28] and C-terminal PF4 peptides PF447_7o 
and PF4 58_70 do react with IL-8 receptors and activate neu-
trophils [28]. The lack of ability to activate neutrophils in the 
designed leucine zipper peptide suggests that residues other 
than heparin binding lysines may be responsible for neutro-
phil activation. Taken together, these results support our de-
sign concept that, by using unrelated sequences as peptide 
design templates, the specific targeted function can be maxi-
mized while other undesired biological properties can be mini-
mized. Therefore, this approach may have important implica-
tions in the development of potential therapeutic agents with 
specific bioactivity and fewer unwanted side effects. 
4. Discussion 
In summary we have demonstrated that a structure-based 
designed synthetic leucine zipper peptide incorporating hypo-
thetical heparin binding sites of four lysine residues displays 
remarkable biological activity of the native PF4 protein. This 
result strongly suggests that four lysine residues positioned 
properly in a helical conformation are essential for heparin 
binding. The designed leucine zipper peptide may also have 
important implications for therapeutic development. For ex-
ample, efficient reversal of heparin anticoagulation is essential 
for a successful completion of open heart surgery in patients 
with cardiopulmonary bypass. Routinely, protamine sulfate is 
being used for this purpose, but this may result in a number 
of complications [29,30]. Recombinant PF4 appears to be a 
safer and more efficient drug as shown in a study in rats and 
baboons. In this regard, the small size and potent activity of 
the designed leucine zipper peptide makes it an ideal target for 
using synthetic chemistry to further develop nonpeptide mi-
metics as potential therapeutic agents. 
The small natural motif approach may have general impli-
cations on the dissection of protein structure-function and 
development of small molecular mimics of functional epitopes 
in a large protein. Smaller peptide fragments containing the 
functional domains of a large protein are useful models to 
study the folding and function of the protein. However, 
when these peptides are synthesized or expressed in isolation 
from the rest of the protein structure, they often lose their 
structural integrity and biological activity, as in the case of the 
PF4 C-terminal peptide (PF4s8_7o). In this study, we have 
shown that the heparin binding activity of the 70-residue 
PF4 protein is reproduced with a 31-residue leucine zipper 
analog. The de novo generation of PF4 function in a much 
smaller leucine zipper peptide provides a striking example for 
the utility of the natural motif approach to mimic unrelated 
large proteins. Recently a systematic approach of using a 
phage display technique to minimize protein functional do-
mains has been reported [31]. While this strategy requires 
extensive stepwise random mutagenesis of a protein domain 
in order to restore its structural integrity and consequently 
biological activity, the natural motif-based design, as demon-
strated in this work can be readily accomplished through a 
direct incorporation of the active sites of a protein into a pre-
existing stable structural template, and thus may present an 
alternative approach to dissect and minimize functional do-
mains of a protein. 
Finally the results of this study demonstrate the feasibility 
of our method in utilizing leucine zipper motifs as templates 
to design novel biological properties. The designed leucine 
zipper peptide adopts a stable conformation and possesses 
significant PF4-like heparin binding activity. Recently others 
have also reported the use of different natural scaffolds of 
scorpion toxins for protein engineering [32]. Taken together, 
these studies suggest that the diverse structural motifs that 
nature has provided us can be exploited to design new func-
tional peptides and proteins. In addition to protein design, we 
have also used the leucine zipper as a template system to study 
the roles of mainchains and sidechains in the stabilization of 
protein structures [33]. It can be expected that the natural 
motif approach will continue to be an effective strategy in 
the studies of protein folding and design. 
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